Integration of novel agents into treatment of myeloma

被引：0

作者：

Lee, Alfred Ian ^{[1
]}

Munshi, Nikhil C. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

CLINICAL LYMPHOMA & MYELOMA | 2007年 / 7卷

关键词：

bortezomib; lenalidomide; thalidomide;

D O I：

10.3816/CLM.2007.s.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

More than 150 years have passed since the first treatments of multiple myeloma were initiated. The past decade has seen a renaissance in the generation of therapies for myeloma as a result of heightened understanding of the molecular pathogenesis of the disease. This review article highlights the development and incorporation of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide into standard myeloma treatment regimens. We also discuss the creation of multiple other myeloma agents currently in phase I/II testing and designed to target specific pathways in myeloma physiology.

引用

页码：S215 / S221

页数：7

共 74 条

[1] TREATMENT FOR MULTIPLE MYELOMA - COMBINATION CHEMOTHERAPY WITH DIFFERENT MELPHALAN DOSE REGIMENS [J].

ALEXANIAN, R ;

HAUT, A ;

KHAN, AU ;

LANE, M ;

MCKELVEY, EM ;

MIGLIORE, PJ ;

STUCKEY, WJ ;

WILSON, HE .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (09) :1680-+

[2] Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma [J].

Alsina, M ;

Fonseca, R ;

Wilson, EF ;

Belle, AN ;

Gerbino, E ;

Price-Troska, T ;

Overton, RM ;

Ahmann, G ;

Bruzek, LM ;

Adjei, AA ;

Kaufmann, SH ;

Wright, JJ ;

Sullivan, D ;

Djulbegovic, B ;

Cantor, AB ;

Greipp, PR ;

Dalton, WS ;

Sebti, SM .

BLOOD, 2004, 103 (09) :3271-3277

[3]

ALWALL N, 1947, LANCET, V253, P388

[4] Thalidomide and dexamethasone for resistant multiple myeloma [J].

Anagnostopoulos, A ;

Weber, D ;

Rankin, K ;

Delasalle, K ;

Alexanian, R .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (05) :768-771

[5]

Anderson K, 2006, J CLIN ONCOL, V24, p423S

[6] Development of farnesyl transferase inhibitors: A review [J].

Appels, NMGM ;

Beijnen, JH ;

Schellens, JHM .

ONCOLOGIST, 2005, 10 (08) :565-578

[7] Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].

Barlogie, B ;

Desikan, R ;

Eddlemon, P ;

Spencer, T ;

Zeldis, J ;

Munshi, N ;

Badros, A ;

Zangari, M ;

Anaissie, E ;

Epstein, J ;

Shaughnessy, J ;

Ayers, D ;

Spoon, D ;

Tricot, G .

BLOOD, 2001, 98 (02) :492-494

[8] Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin [J].

Biehn, Suzanne E. ;

Moore, Dominic T. ;

Voorhees, Peter M. ;

Garcia, Reynaldo A. ;

Lehman, Mary Jo ;

Dees, E. Claire ;

Orlowski, Robert Z. .

ANNALS OF HEMATOLOGY, 2007, 86 (03) :211-216

[9] Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells [J].

Catley, Laurence ;

Weisberg, Ellen ;

Kiziltepe, Tanyel ;

Tai, Yu-Tzu ;

Hideshima, Teru ;

Neri, Paola ;

Tassone, Pierfrancesco ;

Atadja, Peter ;

Chauhan, Dharminder ;

Munshi, Nikhil C. ;

Anderson, Kenneth C. .

BLOOD, 2006, 108 (10) :3441-3449

[10] Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma [J].

Cavo, M ;

Zamagni, E ;

Tosi, P ;

Tacchetti, P ;

Cellini, C ;

Cangini, D ;

de Vivo, A ;

Testoni, N ;

Nicci, C ;

Terragna, C ;

Grafone, T ;

Perrone, G ;

Ceccolini, M ;

Tura, S ;

Baccarani, M .

BLOOD, 2005, 106 (01) :35-39

← 1 2 3 4 5 6 7 8 →